ICH Q9(R1) Quality Risk Management Guidance Document Available
The recent revision is intended to provide guidance on QRM principles and tools that can be used for different aspects of pharmaceutical quality.
FDA announced the publication of a final guidance for industry, Q9(R1) Quality Risk Management, which was prepared with the support of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).
This guidance is a targeted revision of the 2006 guidance for industry Q9 Quality Risk Management, which addresses product availability risks due to manufacturing quality issues, lack of understanding as to what is defined in quality risk management (QRM) work, lack of clarity on risk-based decision-making, and high levels of subjectivity in risk assessments and QRM outputs. The recent revision is intended to provide guidance on QRM principles and tools that can be used for different aspects of pharmaceutical quality.
Additionally, the guidance replaces the draft guidance Q9 (R1) Quality Risk Management that was issued on June 15, 2022.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
